InvestSMART

Firebrick Pharma Limited (ASX:FRE)

ALERT: Price-sensitive ASX Announcement for FRE
Current share price for FRE : $0.034 -0.019 (-35.85%)+
Announcement
Release
24 Feb 2026 12:52PM
Price at Release
$0.053
Full Release
download
Summary
The Appendix 4D and Half-Year Financial Report for Firebrick Pharma Limited, covering the period ending 31 December 2025, outlines a net loss of $1,263,214, with a significant reduction in operating expenses compared to the previous year. The company's revenue from Nasodine Nasal Sprays sales decreased due to a timing issue with a large sale recognized in 2024. Despite the loss, the report reflects optimism about future growth, highlighting recent product launches, including Nasodine Throat Spray, and the expansion of international marketing efforts in the United States, Singapore, Fiji, and potential approval in the Philippines. The company emphasizes a lean operational model with a focus on international partnerships, licensing, and new product development. The report also discusses risks, such as manufacturing and sales development challenges. The directors are confident in securing sufficient funding to continue operations, despite a material uncertainty regarding going concern status. Share capital increased with numerous new shares and options issued during the period.
Key Points
  • Net loss of $1,263,214 for the half-year ended 31 December 2025
  • Revenue from Nasodine Nasal Sprays decreased due to timing of large sale
  • Operating expenses reduced by 17% compared to previous year
  • Launch of Nasodine Throat Spray in Singapore and Fiji
  • Potential approval of Nasodine Nasal Spray in the Philippines
  • Focus on international partnerships and new product development
  • Material uncertainty about going concern status
  • Increase in share capital with new shares and options issued
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.